Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 122 participants.

Also called NCT04830449

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 122 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04830449
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04830449. Randomized; double masking; primary purpose treatment. Start 2020-10-29 (actual); primary completion 2021-08-24 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients
Condition
Hypertension
Intervention (Drug)
HCP1904-2
Intervention (Drug)
RLD2001-2
Lead sponsor
Hanmi Pharmaceutical Company Limited (class: industry)

Record details

Record id
cardio:ct-nct04830449
Content hash
8936ef432d6f6b0d0f5ca6452ecdcbfd22712654226b10fb2e3d2ed38d62cb72